Abstract 572P
Background
Colorectal cancer (CRC) is a heterogeneous disease with multiple subtypes that differ in their clinical and molecular features. The presence of neoantigens derived from somatic mutations is a promising avenue for immunotherapy in CRC. However, the heterogeneity of the neoantigen landscape among CRC subtypes remains unclear.
Methods
We analyzed the whole-genomes and transcriptomes of 1063 CRC patients from a Swedish large cohort. HLA alleles were called by at least two HLA callers including HLA-HD, HLA-LA, Kourami, OptiType, PHLAT, Polysolver, xHLA for each patient. Neoantigens were predicted by pVACseq pipeline using the default settings.
Results
In total, 83,630 MHC class I neoantigens derived from 29,106 mutations (511,159 mutations were inputted) were predicted in 979 patients. Average 6.1 neoantigens were from 4,480 frameshift INDELs while only average 2.3 neoantigens were from 24,276 SNVs. Patients older than 80 years carried more neoantigens than those under 65 years, and women tended to have more neoantigens than men (Wilcoxon test, P<0.01). Tumor neoantigen burden was significantly higher in right-colon, stage II, and hypermutated (HM) tumors (P<0.0001). In total, 850 mutations were predicted to generate neoantigens in at least two patients, including KRAS G12D (6.3%), RNF43 G659X (6.1%), KRAS G12V (5.2%), TBC1D23 K647X (2.9%), and MSH3 K381X (2.8%). Neoantigen numbers from PODXL2 and CRAT mutations were significantly higher in consensus molecular subtype (CMS) 3 tumors, whereas neoantigens from JAG2 mutations were more common in CMS2 (chi-square test, P <0.05). Neoantigens derived from DNAH3, KRAS and ERBB2 mutations (37%, 47% and 52% respectively) in non-HM patients were significantly more than those (5%, 14% and 13% respectively) in HM patients. Furthermore, in stage I-III, nHM patients (n=11) with DNAH3 neoantigens have significantly longer overall survival than patients (n=24) with only DNAH3 mutations.
Conclusions
Our study constitutes the largest neoantigen dataset from integrated genome and transcriptome of CRC to date and illustrates the heterogeneity of the neoantigen landscape among CRC subtypes. The identified neoantigens may contribute to future individualized CRC immunotherapies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Uppsala University; Umeå University; BGI-Shenzhen.
Funding
The Swedish Cancer Society; the Uppsala Cancer Foundation; the Guangdong Provincial Key Laboratory of Human Disease Genomics; the Swedish Government (CancerUU); the Erling-Persson Foundation.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
528P - Progression risk after pregnancy in patients with glioma
Presenter: Annette Leibetseder
Session: Poster session 10
529P - Post-marketing surveillance data from patients ≥70 years of age with central nervous system malignancies treated with Tumor Treating Fields (TTFields) therapy between 2011–2022
Presenter: Wenyin Shi
Session: Poster session 10
530P - Ultra low bevacizumab (BEVULTRA-100) as a novel approach in symptomatic management of high grade glioma: Can minimal dose make a difference?
Presenter: P ANURADHA
Session: Poster session 10
531P - Tumor treating fields therapy for glioblastoma: Identifying needs and satisfaction of new and long-term users
Presenter: Eleni T. Batzianouli
Session: Poster session 10
532P - Nitric oxide is a target by a combo-drug for glioblastoma treatment
Presenter: Manish Tripathi
Session: Poster session 10
533P - Oligodendrogliomas: What is the impact after the introduction of the WHO molecular classification?
Presenter: Maria Angeles Vaz Salgado
Session: Poster session 10
534P - Glioblastoma treatment in patients older than 60 years: Hypofractionated radiotherapy and temozolomide versus conventional radiotherapy and temozolomide
Presenter: Teresa Pacheco
Session: Poster session 10
535P - Hypofractionated radiotherapy in fit elderly patients with glioblastoma: Relevant or detrimental?
Presenter: Carla Martín Abreu
Session: Poster session 10
536P - Safety and efficacy of silibinin in patients with brain metastases after stereotactic radiosurgery (SRS): The SUSTAIN trial
Presenter: Niccolò Bertini
Session: Poster session 10
537P - S100A9 serum levels are associated with survival prognosis in patients with brain metastases
Presenter: Ariane Steindl
Session: Poster session 10